Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises CELLINK in conjunction with the acquisition of Dispendix GmbH
Mandate

Vinge advises CELLINK in conjunction with the acquisition of Dispendix GmbH

November 30, 2018 M&A

Vinge has advised CELLINK AB, listed on First North Stockholm, in connection with the acquisition of all shares in Dispendix GmbH. Dispendix’s operations focus on bio dispensing technology and its patented technology emanates from a 10-year development within the German research institute Fraunhofer.

The acquisition strengthens CELLINK’s offering of complete 3D bioprint solutions. The purchase price amounts to MEUR 5 as well as the assumption of net debt in a maximum amount of MEUR 0.4. The purchase price is paid with MEUR 2 in cash and MEUR 3 with CELLINK class B shares (issue in kind to be resolved by CELLINK’s extraordinary general meeting during December 2018).

Vinge’s team primarily consisted of responsible partner Anders Strid, Daniel Lennartsson (M&A) and Alexander Lindeberg (IP). Noerr through, among others, responsible partner Dr. Holger Alfes, acted as local counsel in Germany.
 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025